Processa Pharmaceuticals, Inc. Deferred Tax Assets, Net of Valuation Allowance, Current
Processa Pharmaceuticals, Inc. (PCSA) had Deferred Tax Assets, Net of Valuation Allowance, Current of $5.07 million as of 2016-12-31, per its 10-K filed 2017-09-25.
Discontinued › Notes › Income Taxes
us-gaap:DeferredTaxAssetsNetCurrent · last filed 2017-09-25
- 2016-12-31: Deferred Tax Assets, Net of Valuation Allowance, Current $5.07M.
- 2015-12-31: Deferred Tax Assets, Net of Valuation Allowance, Current $4.94M; Deferred Tax Assets, Net of Valuation Allowance, Current as first filed $5.16M.
- 2014-12-31: Deferred Tax Assets, Net of Valuation Allowance, Current $3.41M.
| Period end | Deferred Tax Assets, Net of Valuation Allowance, Current | Deferred Tax Assets, Net of Valuation Allowance, Current as first filed |
|---|---|---|
| 2016-12-31 | $5.07M 10-K · filed 2017-09-25 | |
| 2015-12-31 | $4.94M 10-K · filed 2017-09-25 | $5.16M 10-K · filed 2017-06-19 |
| 2014-12-31 | $3.41M 10-K · filed 2017-06-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| ProPhase Labs, Inc. (PRPH) | United States | $0.006B | -0.06 |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| Lakewood-Amedex Biotherapeutics Inc. (LABT) | United States | $0.004B | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| 60 DEGREES PHARMACEUTICALS, INC. (SXTP) | United States | $0.004B | -0.59 |